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The crucial role of potassium (K) channels as
primary regulators of intrinsic electrical properties
in excitable cells is well established; moreover, in
excitable and nonexcitable cells, K channels con-
trol cell volume, proliferation, differentiation, and
survival. Such an extraordinary heterogeneity of
functions in each cell type at various differentia-
tion stages is accomplished through the expression
of a specific pattern of K currents, each with
distinct subcellular localization, biophysical prop-
erties, modulation, and pharmacological profile. In
fact, electrophysiological studies in a variety of cel-
lular models have revealed an astonishing func-
tional diversity of the K current family, often
anticipating the remarkable genetic and structural
heterogeneity of K channels (112).
Among voltage-gated K channel (Kv) genes, the
Kv7 (KCNQ) family comprises five members
(Kv7.1–5); Kv7.1 is mainly expressed in cardiac
cells, whereas Kv7.2, Kv7.3, Kv7.4, and Kv7.5 give
rise to K currents widely distributed in neuronal
and primary sensory cells (FIGURE 1). The spec-
trum of functional roles attributed to Kv7 subunits
has widened further following their description in
smooth muscle cells of vascular and visceral tis-
sues and in skeletal muscle cells. The aim of the
present review will be to summarize the current
knowledge about the overall architecture, tissue
distribution, biophysical properties, regulation and
pathophysiological roles of Kv7 channels, thereby
setting the basis for their increasingly important
pharmacological role.
Topological Arrangement of Kv7
Subunits and Main Regulatory
Sites
Similar to other Kvs, Kv7 channels are tetramers of
identical or compatible subunits; each Kv7 subunit
shows a topological arrangement with six trans-
membrane segments (S1–S6), and intracellular
NH2 and COOH termini (FIGURE 2). The region
encompassing segments S1–S4 forms the voltage-
sensing domain (VSD), whereas the S5–S6 region
forms the ion-selective pore. As in other Kvs, in Kv7
channels, the S4 segment contains from four to six
positively charged arginines (Rs) separated by two
to three uncharged residues; unlike other Kv chan-
nels, the third R is replaced by a neutral glutamine
residue. The K selectivity filter has the canonical
GYGD sequence. Kv7 channel function at various
cellular sites is influenced by accessory subunits
characterized by a single membrane-spanning do-
main and encoded by the KCNE gene family (65,
104), similar to other Kv channels (1, 2). A long
COOH-terminal region is characteristic in Kv7 sub-
units; at this location, sites determining hetero-
meric and homomeric assembly, interaction with
regulatory molecules, subcellular localization, and
binding of accessory proteins have been identified (31).
Calmodulin
The regulatory protein calmodulin (CaM) appears
to be constitutively tethered to the COOH-terminal
region of Kv7.2/3 channels, irrespective of the in-
tracellular Ca2 concentration ([Ca2]i) (111, 118).
Secondary structure analysis of this region predicts
four -helices (A, B, C, and D) conserved in all Kv7
family members. Of these, helices A and B contain
CaM-binding sequences, an IQ-like sequence in
helix A, and two overlapping 1-5-10 motifs in helix
B. The precise mechanism by which CaM regulates
Kv7 channel function is still highly debated. In
general, CaM is believed to play a key role for Kv7
channel folding and trafficking; mutations that af-
fect CaM binding profoundly impair channel mat-
uration and plasmamembrane expression (27). In
addition to this “structural” function of CaM, it has
also been shown that Kv7 currents are highly sen-
sitive to [Ca2]i and that CaMacts as their Ca
2 sensor;
such a mechanism would mediate channel modula-
tion by [Ca2]i-mobilizing receptors (34).
Syntaxin 1A
Helix-A appears to mediate Kv7.2 direct interaction
with the plasma membrane protein syntaxin 1A,
possibly a crucial phenomenon for Kv7.2 subunits
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targeting at presynaptic sites (FIGURE 1; Ref. 74)
where they regulate neurotransmitter release
(62, 63).
Phosphatidylinositol-(4,5)-Bisphosphate
A decrease in phosphatidylinositol-(4,5)-bisphos-
phate (PIP2) membrane concentration is the main
biochemical signal by which agonists acting at
Gq/11-coupled metabotropic receptors regulate the
activity of Kv7 channels in native and recombinant
sytems. In addition, the differences in the single
channel open probability (po) among channels
formed by Kv7.2, Kv7.3, Kv7.4, and Kv7.5 subunits
appear to be dependent on their intrinsic affinities
for intracellular PIP2 (55). Indeed, higher PIP2 con-
centrations increase the po of homomeric and het-
eromeric channels formed by Kv7 subunits, thus
stabilizing their open state. In support of this
hypothesis is the higher sensitivity of “low po”
Kv7.2, Kv7.4, and Kv7.5 channels to receptor-de-
pendent PIP2 depletion compared with “high po”
Kv7.3 channels (Table 1; Ref. 35). Although initial
studies identified a histidine residue in the proxi-
mal COOH terminus in Kv7.2 (121) as the receptor
site for PIP2-induced modulation of Kv7 channels,
more recent evidence also suggests involvement
of a region rich in positively charged residues loca-
ted between helix A and B of the COOH-terminal
domain (35).
Phosphorylation
The COOH-terminus region of Kv7.2 subunits con-
tains the binding site for the anchoring protein
AKAP79/150 that forms a trimeric complex with
protein kinase C (PKC; Ref. 36). Although the direct
regulation of Kv7 channels by PKC and how this
FIGURE 1. Tissue distribution of Kv7 subunits
The different panels in the figure report the principal sites of expression for each Kv7 channel subunit. In addition to those shown, it should be
noted that Kv7.1 subunit expression has been detected in epithelial cells from various tissues not shown in the figure (lungs, pancreas, liver,
thymus, kidneys, adrenal glands, and testis).
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interferes with the CaM- and PIP2-induced chan-
nel regulation is still controversial, the removal of
two putative PKC phosphorylation sites in helix B
largely prevents the inhibition of Kv7.2 currents by
agonists acting at Gq/11-coupled metabotropic re-
ceptors (36). Kv7.1 does not form complexes with
AKAP79/150; instead, it interacts with the anchor-
ing protein yotiao, which binds protein kinase A
(64). It has been recently shown that Ca2-bound
CaM disrupts the functional interactions between
AKAP79 and Kv7 channels, likely due to CaM bind-
ing to the channels at an overlapping site with
AKAP79/150 (5). The Kv7 COOH-terminal region
also contains tyrosine residues that can be phos-
phorylated via receptor and nonreceptor tyrosine
kinases. Among the latter, Src phosphorylates
Kv7.3, Kv7.4, and Kv7.5, leading to current sup-
pression (29). In Kv7.3, Src recognizes two tyrosine
residues, one in the NH2 terminus (Y67) and the
other in the COOH terminus at helix A (Y349) (56).
Moreover, activation of EGF receptors inhibits
Kv7.2/3 currents by activating PIP2 hydrolysis and
phosphorylation of the same tyrosine residues in-
volved in Src-dependent modulation (43). Addi-
tional residues phosphorylated by endogenous
kinases on intact channel proteins in living mam-
malian cells have been identified in the S4-S5
linker using mass spectrometry (102).
Subunit Interaction Domain
In Kv7 COOH terminus, further down to CaM-
binding helices A and B, regions involved in multi-
merization and subunit-specific heteromerization
have been identified, which correspond to helices C
and D (90). At this location, coiled-coil interactions
among subunits occur, as also recently revealed by
structural analysis of the D helix in Kv7.4 channels
(38), and it has also been suggested that this sub-
unit interaction domain (sid) also acts as a plat-
form for Kv7 interactions with accessory KCNE
subunits (32), although additional sites (in S6 and
in the VSD) also have been implicated (57).
Nedd4–2
The ubiquitin-protein ligase Nedd4–2 regulates
membrane expression of Kv7.2/3 and Kv7.3/5
channels (26), as well as of Kv7.1/KCNE1 het-
eromultimers (42). Nedd4–2 downregulates the
current carried by these channels, possibly by pro-
moting ubiquitination, internalization, and degra-
dation; a PY motif located at the COOH-terminal
end of the Kv7.1 subunit has been identified as
crucial in this process, whereas the role of the same
region in Kv7.2/3 subunits is less defined.
Ankyrin-G
In the distal end of Kv7.2 and Kv7.3 COOH termini
(but not in other Kv7 subunits), an interaction
domain for the adaptor protein Ankyrin-G has
been identified (71), which allows heteromeric
Kv7.2/3 channels to localize at the axonal initial
segment and Ranvier nodes, crucial sites for action
potential initiation and propagation (FIGURE 1).
Molecular Identification of the
Kv7 Genes: Role in Human
Diseases
The identification of themolecular defects responsible
for humangenetically transmitted channelopathies has
FIGURE 2. Schematic representation of a single Kv7.2 subunit
The approximate position of the binding domain for PIP2 in the COOH terminus is indicated. A, B, C, and D correspond to the four hypothetical
-helical regions identified in Ref. 118. sid, Subunit interaction domain; CaM, calmodulin; AKAP, A-kinase-anchoring protein; PKC, protein kinase C;
Ank-G, ankyrin-G; PIP2, phosphatidylinositol-(4,5)-bisphosphate.
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been instrumental for the cloning of the Kv7 genes
and for the identification of their protein products as
major molecular determinants of several currents at
specific cellular sites. Most of these genetic defects
impair Kv7 channel regulation of cell intrinsic elec-
trical properties; therefore, Kv7 channelopathies are
often associated with an enhanced cellular excitabil-
ity unopposed by the “braking effect” exerted by Kv7
channels, hence, the title of this review.
Kv7.1, Arrhythmias, and IKs
The first human channelopathy in which a Kv7
gene defect was discovered is the Long QT Syn-
drome (LQTS), an arrhythmic disorder character-
ized by the lengthening of the QT interval of the
electrocardiogram, indicative of a delayed cardiac
action potential repolarization. Most patients af-
fected by LQTS are asymptomatic until some event
(strenuous exercise, stress, drugs, etc.) leads to tor-
sades de pointes, a distinctive re-entrant ventricu-
lar tachycardia in which the amplitude of the QRS
complex varies around the isoelectric line. Tor-
sades de pointes can self-terminate or degenerate
into ventricular fibrillation. In the most common
form (LQTS-1), accounting for over 50% of the
LQTS cases, mutations in the gene encoding for the
K channel subunit Kv7.1 (previously known as
KvLQT1 or KCNQ1) have been found (109). LQTS
caused by Kv7.1 mutations can be transmitted in a
dominant or recessive manner; in the first case (the
Romano-Ward syndrome), only cardiac symptoms
are present in heterozygous affected individuals,
whereas in homozygous carriers of the recessive
form (the Jervell and Lange-Nielsen syndrome),
bilateral deafness accompanies the severe cardiac
dysfunction. Kv7.1 subunits, when expressed in
heterologous systems together with the accessory
-subunit KCNE1, form channels that give rise to
voltage-gated currents whose biophysical and
pharmacological properties closely resembled those of
the IKs component of the cardiac delayed
rectifier IK (FIGURE 3; Refs. 77a, 84, 104a). In fact,
in guinea-pig atrial and ventricular myocytes (82,
83), similar to human atrial and ventricular myo-
cytes, canine ventricular cells, and rabbit ventric-
ular cells, two prominent components of IK,
referred to as IKr (IK,rapid) and IKs (IK,slow), can be
defined on the basis of their differential sensitivity
to blockade by class III anti-arrhythmics, including
dofetilide, E-4031, and sotalol. Drug-sensitive IKr
activates and inactivates rapidly, displaying
marked inward rectification; on the other hand,
drug-resistant IKs activates and deactivates slowly
during membrane depolarization and hyperpolar-
ization, respectively, shows very little rectification,
and fails to inactivate significantly (FIGURE 3; Ta-
ble 1). IKr and IKs also differ in their single-channel
conductances (10–13 pS for IKr, 2–8 pS for IKs) (93,
107, 114). The functional role of IKs for cardiac
repolarization in different species has been a mat-
ter of extensive debate; in human ventricular cells,
IKs contributes to the repolarization process only to
a minimal extent under normal circumstances, but
Table 1. Kv7 family genes and proteins
Kv7
Member
Locus Disease Exons and Splice Variants Biophysical Parameters
V1/2, mV k, mV/e-fold  act, ms
at 40 mV
Kv7.1 11p15.5 LQTS1 JLNS1 SQTS
FAF
Six splice variants (isoforms 0–5): isoform
1 is the primary isoform and is
composed of 16 exons coding for a
protein of 676 amino acids
20a 12a 90b
Kv7.2 20q13.3 BFNS Five splice variants; the longest isoform
A is composed of 17 exons that code
for a protein of 872 amino acids
30f 8f 130b
Kv7.3 8q24 BFNS No splice variants; 15 exons coding for a
protein of 872 amino acids
40f 7f 60b
Kv7.4 1p34 DFNA2 Two isoforms: the longest A consists of
14 exons encoding for a protein of
695 amino acids
20f 13f 160b
Kv7.5 6q14 Five splice variants. Isoform 4 is the
longest, with 14 exons that translate in
a protein of 951 amino acids. Isoform
1 is predominantly expressed in the
brain, while isoforms 2 and 3 are
mainly expressed in skeletal muscle
40f 7f 150b
Data in table are adapted from Refs. a104a, b29, c77a, d75a, e103, f67, g54, h98, i116a. LQTS1, long QT syndrome type 1; JLNS1, Jervell
and Lange-Nielsen syndrome type 1; SQTS, short QT syndrome; FAF, familial atrial fibrillation; BFNS, Benign Familial Neonatal Sei-
zures; DFNA2, autosomal dominant type 2 deafness. *Low po20%; high po	80%; **Data from Kv7.2/Kv7.3 heteromeric channels (Ref.
108).
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it provides an important safety mechanism to pre-
vent excessive and dangerous repolarization
lengthening when repolarization is prolonged be-
yond normal and/or sympathetic tone is elevated
(45, 46). In fact, downregulation of IKs, either as a
consequence of diseases such as heart failure, di-
abetes, or cardiac hypertrophy, or of mutation-
induced loss of function (as in LQTS-1), or of its
pharmacological inhibition, does not produce a
marked repolarization lengthening but makes the
repolarization less stable and the heart vulnerable
toward repolarization abnormalities and torsades
de pointes arrhythmias. Modeling studies confirm
a crucial role for IKs in providing a “repolarization
reserve” when other repolarizing currents (e.g., IKr)
are compromised (79). As recently reviewed (72),
almost 300 mutations have been identified in Kv7.1
in LQTS-1 patients; several others have been found
in the KCNE1 gene (LQTS-5) (106). In both LQTS-1
and LQTS-5, the disease pathogenetic mechanism
is an impairment of IKs function (loss-of-function
mutations). Noticeably, a few gain-of-function mu-
tations in both Kv7.1 and KCNE1 have been linked
to familial atrial fibrillation (FAF; Ref. 18) or to
short QT syndrome (SQTS; Ref. 10).
In addition to cardiomyocytes, Kv7.1 mRNA is
widely distributed in epithelial tissues, often in
association with various members of the KCNE
gene family (FIGURE 1). In particular, voltage-
dependent Kv7.1 channels can be converted to
voltage-independent, constitutively open K leak
channels by co-assembly with the KCNE2 or
KCNE3 ancillary subunits (86). In gastric parietal
cells, Kv7.1-KCNE2 channels provide an apical K
recycling pathway required for acidification by the
H-K-ATPase (33, 88); consistent with this, a se-
vere gastric phenotype with impaired acid secretion
and gastric mucosal hyperplasia has been observed
in Kv7.1 (52) or KCNE2 (76) knockout mice. In the
colon, basolateral Kv7.1-KCNE3 channels provide a
driving force for cAMP-stimulated Cl secretion (86).
Noticeably, in murine gastrointestinal tissue, despite
abundant expression in enterocytes, no evidence for
Kv7.1 expression was found in smooth muscle cells
(Ref. 41; see below). Kv7.1 and KCNE2 also form
constitutively active K channels in thyrocytes, and
Kv7.1-KCNE2 channels regulate normal thyroid hor-
mone biosynthesis (77). Kv7.1 is also expressed in
pancreatic -cells, where it regulates insulin secre-
tion; Kv7.1 has been recently identified as a strong
susceptibility gene for Type 2 diabetes in Japanese
(105) and Scandinavians (44). Finally, delayed-recti-
fier K currents in murine portal vein myocytes are
inhibited by the selective Kv7 channel blocker lin-
opirdine, providing the first functional evidence for
Kv7 channels in vascular smooth muscle (69); in ad-
dition to Kv7.1, expression of other Kv7 members
likely contributes to this pharmacological sensitivity
(Refs. 58, 116; see below). Recently, Kv7.1 transcripts
and proteins have been shown to be expressed in
brain regions involved in epileptogenesis and in
Biophysical Parameters Pharmacology
 deact, ms at
60 mV
Po g, pS TEA
(IC50, mM)
Lino
(IC50, 
M)
XE-991
(IC50, 
M)
RET
(EC50, 
M)
450b lowc* 8c 5d 9d 1d 	100e
150b lowg 6g 0.3d 4d 1d 2e
100b highg 8g 	30d 5d 1** 1e
100b lowg 2g 3d 	10d,h 	5h 5e
120b lowg 2g 	30d 	10d 	25d 6i
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brain stem nuclei involved in autonomic control of
cardiac function (30).
Kv7.2, Kv7.3, Epilepsy, and IKM
Kv7.2 and Kv7.3 genes were characterized upon
identification of the molecular defects responsible
for Benign Familial Neonatal Seizures (BFNS), a
rare autosomal-dominant idiopathic epilepsy of
the newborn characterized by the occurrence of
focal, multifocal, or generalized tonic-clonic con-
vulsions starting around day 3 of postnatal life and
spontaneously disappearing after a few weeks or
months (73). Using positional cloning strategies,
the genes altered in both EBN1 (11, 96) and EBN2
(16), two chromosomal loci previously linked to
BFNS, were identified and found to belong to the
same gene family of Kv7.1; they were therefore
named KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3), re-
spectively. Mutations in Kv7.2 are 10 times more
frequent than in Kv7.3; all Kv7.3 mutations de-
scribed to date are missense, whereas Kv7.2 mu-
tations consist of truncations, splice site defects,
FIGURE 3. A summary of voltage-gated K currents possibly underlined by Kv7 subunits
A: an example of IKs (data from Ref. 82). Left: outward K
 currents recorded in guinea-pig ventricular myocytes after exposure to 5 
M E-4031.
Currents were recorded during 550-ms pulses to 20, 0, 20, and 40 mV from a holding potential of 40 mV. Right: the I/V relation for the total
IK and the two components IKr (E-4031-sensitive) and IKs (E-4031-insensitive). B: an example of IKM (data taken from Ref. 108). In rat sympathetic
neurons of the cervical ganglia, currents were activated by holding the cells at 60 mV and depolarizing to 0 mV (10-mV increments; top left), and
deactivated with hyperpolarizing pulses up to 80 mV from an holding potential of 30 mV (10-mV increments; bottom middle). Top right: a
conductance-voltage curve fitted with a single Boltzmann function (V1/2  44 mV; k  8.8 mV/e-fold). Middle and bottom: the effects of retiga-
bine (3 
M), an IKM activator, and XE-991 (10 
M), an IKM blocker, respectively, on somatic excitability of sympathetic neurons from the superior
cervical ganglion (data from Refs. 103 and 120, respectively). C: an example of IK(n) [data taken from Ref. 61 (left) and Ref. 37 (right)]. IK(n) was iden-
tified in mouse cochlear outer hair cells at P12 as the voltage-dependent membrane current remaining after subtraction from the control current of
the linopiridine (200 
M)-sensitive component (holding voltage: 84 mV; test pulses from 124 mV to 34 mV, in 10-mV increments). Right: a con-
ductance-voltage curve fitted with a single Boltzmann function (V1/2  86 mV; k  17 mV/e-fold). D: an example of IKx (data taken from Ref.
51). IKx was recorded in rod photoreceptors from tiger salamander held at 30 mV at voltages between 90 and 0 mV, as indicated. The activa-
tion curve shown at right resulted in a V1/2 of 54 mV and a slope factor (k) of 5.4 mV/e-fold.
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or missense, non-sense, and frame-shift muta-
tions, as well as sub-microscopic deletions or dupli-
cations. Kv7.2 mutations have also been detected in
sporadic cases of benign neonatal seizures (9).
Kv7.2 subunits have been heterologously ex-
pressed in Xenopus oocytes and in a wide range of
mammalian cells. Homomeric Kv7.2 channels carry
robust K-selective currents activated by depolariza-
tion at membrane potentials around 50 mV; these
currents exhibit slow activation and deactivation ki-
netics and lack significant inactivation (Table 1). Cur-
rents carried by Kv7.3 homomultimers are rather
small and activate at more negative potentials (ap-
proximately 60 mV); at the single-channel level,
Kv7.3 channels show the highest opening probability
and unitary conductance among Kv7 members (55).
Expression of Kv7.2 and Kv7.3 subunits in the same
cell generates currents whose amplitude is10 times
larger than that expected from the simple summa-
tion of the currents produced by the Kv7.2 or Kv7.3
homomultimers (108, 113). An higher opening prob-
ability of Kv7.2/Kv7.3 heteromers compared with
Kv7.2 homomers, together with a two- to threefold
increase in the number of channel-forming subunits
expressed at the membrane (89) contributes to this
phenomenon.
Several studies in heterologous expression sys-
tems have focused on the molecular mechanism by
which BFNS-causingmutations affect the function of
Kv7.2/Kv7.3 subunits, shedding light on disease
pathogenesis (9). Although some mutations drasti-
cally decrease steady-state cellular levels of channel
subunits, others affect their intracellular trafficking
(99) and polarized targeting (20), or their function
once normally inserted into the plasmamembrane
(15, 22, 100). Based on this evidence, it has been
proposed that a mild (20–30%) decrease of IKM func-
tion appears sufficient to cause BFNS (85) and that
haploinsufficiency is the primary pathogenetic
mechanism for both familial and sporadic cases of
BFNS.
More importantly, heterologous expression studies
revealed that the biophysical and pharmacological
properties of the Kv7.2/Kv7.3 heteromultimers re-
capitulate those of the native M-current (IKM)
(108), a voltage-gated K current first isolated in
sympathetic neurons of the bullfrog in the 1980s
(FIGURE 3B; Ref. 12). In these cells, acetylcholine
released from preganglionic cells, in addition to
fast nicotininc excitatory postsynaptic potentials
(fEPSPs), was known to trigger slow excitatory
membrane responses (sEPSPs) (25). Compared
with nicotinic fEPSPs, these slow responses
showed long synaptic delays (tenths to hundreds of
milliseconds), were long-lasting (enduring for
many seconds) and were due to acetylcholine
binding to muscarinic receptors. sEPSPs were ac-
companied by a decrease in membrane conductance
of the postganglionic cell (48), an effect consequent to
the suppression of a K conductance (110), later iden-
tified as IKM. Following its discovery in amphibian
sympathetic neurons, IKM was soon described in
rat superior cervical ganglion (SCG) cells (21) and
in a variety of central neurons, including mamma-
lian hippocampal and cortical pyramidal cells (60).
Kv7.2 and possibly Kv7.3 subunits also appear to
mediate the slow K current observed in nodes of
Ranvier of mammalian peripheral myelinated fi-
bers (24, 91). IKM is a non-inactivating, voltage-
dependent K current that activates in a time- and
voltage-dependent manner at60 mV, close to the
resting membrane potential and, in cells express-
ing M1, M3, or M5 muscarinic receptors, is sup-
pressed by muscarinic receptor stimulation (hence
its name). IKM opposes cell depolarization by in-
coming stimuli, therefore inhibiting neuronal hy-
perexcitability and causing spike frequency
adaptation during sustained depolarizations. Mus-
carinic receptor activation, by suppressing IKM, de-
polarizes the cells and enhances membrane
excitability, causing tonic firing. Although it was
originally believed that activation of IKM was too
slow to influence the repolarization of solitary
spikes, it has been recently shown that IKM (120)
activates during the spike after depolarization and
limits its duration, thereby precluding its escala-
tion to a burst (117). In addition to muscarinic
receptors, agonists binding at several Gq/11-
coupled receptors, by activating phospholipase C
and depleting membrane PIP2 levels, can suppress
IKM. The existence of additional IKM modulatory
pathways, possibly exploited by other neurotrans-
mitters, has also been hypothesized (23, 34).
Given the inhibitory role of IKM on neuronal excit-
ability, together with the observation that IKM-form-
ing Kv7.2 and Kv7.3 subunits are widely distributed
in the hippocampus, neocortex, and cerebellar cortex
at key sites for neuronal network oscillations and
synchronization control, it is perhaps not too surpris-
ing that mutations in Kv7.2 or Kv7.3 genes can cause
epilepsy in humans. The specific vulnerability of the
neonatal brain to these mutations is likely due to the
excitatory actions of GABA in early life (19), com-
bined to a low density and more depolarized voltage
range of activation of IKM (81), which would render
neonatal neurons more sensitive to the “epilepto-
genic” consequences of IKM dysfunction caused
by BFNS mutations. Likewise, the developmental
changes in GABA’s action, together with the in-
creased expression and hyperpolarization shift in
the activation threshold for IKM, can explain the
disappearance of spontaneous seizures in BFNS
patients with brain maturation.
Noteworthy, Kv7.2/3 channels appear as emerging
targets for pharmacological interventions directed
against human hyperexcitability diseases. As amatter
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of fact, IKM openers like retigabine (103) are effective
in a broad range of in vitro and in vivo models pre-
dictive of anticonvulsant activity, also showing po-
tent antiepileptic activities in humans (6, 75a).
Besides epilepsy, Kv7.2/3 channel modulators may
provide clinical benefit also in other neuropsychiat-
ric diseases, ranging from pain to migraine, anxiety,
dystonia, sensory deficits, and neurodegenerative
diseases (66).
Kv7.4, Deafness, and M-Like Currents
Hearing loss is the most frequent inherited sensory
defect in humans, with genetic factors playing a cru-
cial role. Genetically transmitted hearing loss can be
associated with other abnormalities (syndromic) or
occur in isolation (nonsyndromic). Among the large
number of genes associated with genetically trans-
mitted deafness, those that encode for ion channels
involved in sensory transduction in cochlear hair
cells have received particular attention. In fact, the
gene encoding for Kv7.4 was cloned by sequence
homology to Kv7.3 and found as the causative gene
for autosomal dominant type 2 deafness (DFNA2), a
progressive form of sensorineural hearing loss, start-
ing in the high frequencies and also affecting the
middle and low frequencies later in life (49). Most
DFNA2-causing mutations in Kv7.4 are missense al-
terations affecting amino acids located within or
close to the channel pore (97); these mutations cause
hearing loss via a dominant-negative effect as mu-
tant subunits interfere with the assembly and/or
function of the wild-type subunits in the inner ear
(49). Some DFNA2-causing mutations in Kv7.4 are
deletions that result in haploinsufficiency, since the
mutant subunits fail to interact with the normal pro-
tein encoded by the wild-type allele; the hearing loss
associated with these mutations is milder in low and
mid frequencies, more severe in high frequencies,
and later in onset than the hearing loss associated to
missense mutations (97).
When expressed in Xenopus oocytes, Kv7.4 sub-
units yield voltage-dependent, K-selective currents
that activate slowly upon depolarization around40
mV (Table 1); compared with other Kv7 channels,
current activation kinetics of Kv7.4 channels are sig-
nificantly slower, whereas the deactivation process
seems to be faster (49). Despite showing the lowest
opening probability (0.07) and unitary conductance
(2.1 pS) among Kv7 channels (54, 55), homomeric
Kv7.4 channels give rise to very large currents, sug-
gesting a very high density of functional Kv7.4 chan-
nels at the plasmamembrane (119) and allowing one
to record their gating currents (67). Kv7.4 subunits do
not co-assemble with Kv7.1 or Kv7.2 subunits, but
heteromeric channels composed of Kv7.3 and Kv7.4
subunits can be generated in heterologous expres-
sion systems; formation of Kv7.4/Kv7.5 heteromers
in vivo has also been proposed (14).
High levels of Kv7.4 expression have been de-
scribed in the basolateral membrane of cochlear
outer hair cells (OHCs) (FIGURE 1), where Kv7.4
subunits are thought to provide a major contribu-
tion to the K conductance defined as IK,n, a volt-
age-dependent K current first described in OHC
of the guinea-pig organ of Corti (FIGURE 3C; Ref.
37). IK,n activates near normal resting potentials of
70 to 80 mV and deactivates below 90 mV;
therefore, its function would be to hold the cell
near the Nernst equilibrium potential for K ions,
thereby maximizing the driving force for K entry
through the apical transducer. K currents having
a negative activation range have been also de-
scribed in mouse and rat inner hair cells (IHCs);
these currents contribute to the resting conduc-
tance of the IHC, thereby maintaining low intra-
cellular Ca2 levels by favoring the closed state of
Ca2 channels. Also in IHCs, Kv7.4 expression has
been detected by immunofluorescence (70) or in
situ hybridization and RT-PCR analysis (8), al-
though at a lower level than in OHCs; these obser-
vations, in one with the temporal overlap between
Kv7.4 and IK,n occurrence during ontogenesis, pro-
vide solid evidence for Kv7.4 subunits contributing
to IK,n also in IHCs (47). Similarly, in vestibular
epithelia, type I hair cells express a high density of
K channels with an activation range at very neg-
ative voltages, overlapping the resting membrane
potential; this IKM-like current, described as gKI
(75) or gK,L (80) is responsible for the extremely low
input resistances of type I cells compared with type
II cells. Although Kv7.4 has been suggested to pro-
vide a major contribution to the described IKM-like
currents, significant functional and pharmacolog-
ical differences exist between Kv7.4-mediated cur-
rents in heterologous expression systems and
native IK,n or g(K,L) in cochlear and vestibular hair
cells, respectively. In fact, IK,n (59) and gK,L (17)
voltage range of activation is far more negative
(IK,n: V1/2  92 mV; gK,L: V1/2  73 mV) than
that of Kv7.4 homomultimers (49, 92); furthermore,
activation kinetics are much slower in recombi-
nant channels (49, 98). In addition, IK,n is blocked
by linopirdine with an IC50 of 0.7 
M (61), whereas
Kv7.4 homomers and Kv7.3/4 heteromers have an
higher IC50 for this compound. It has been sug-
gested that such differences might be attributable
to modulation of Kv7.4 by interacting KCNE sub-
units; in particular, KCNE4 appears responsible for
the marked leftward shift of the activation curve of
IK,n in vivo (101).
In isolated salamander rod photoreceptors, Attwell
and Wilson (3) characterized the ionic basis for the
strong outward rectification observed in these cells
for potentials more positive than about 35 mV and
found that the voltage- and time-dependent current
IA was composed of two ionic current components,
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one TEA-sensitive activated by depolarization (IKx)
(4) and another Cs-sensitive activated by hyperpo-
larization (Ih). Further studies (7) revealed that IKx is
a standing (non-inactivating) outward K current
that deactivates slowly when the cell is hyperpolar-
ized, thus showing a voltage and time dependence
similar to that of IKM (FIGURE 3D). In rods, IKx is
believed to contribute prominently in setting the
dark resting potential and in accelerating the re-
sponse to dim light (50, 51). Whether Kv7.4, whose
cDNA was first isolated from a human retinal library
(49), provides a significant contribution to IKx (98)
has not been demonstrated.
Beside shaping the responses to auditory, vestib-
ular, and visual inputs in primary sensory cells,
M-like currents have been long known to play im-
portant roles in smooth muscle cells from vascular
and nonvascular organs. Perhaps the first demon-
stration of a K current resembling IKM in the
smooth muscle was in amphibian gastric smooth
muscle cells (95); in these cells, membrane depo-
larization at rather negative values (less than 70
mV) triggered the slow activation of a K-selective
current that was suppressed by cholinergic ago-
nists. In vascular smooth muscle cells, currents
having similar biophysical and pharmacological
profiles were later found in all branches of the
rabbit pulmonary arterial tree and named IK(N) to
highlight their negative activation voltage range
(28). The first hints into the molecular identifica-
tion of IK(N) in vascular smooth muscle cells came
from pharmacological studies: the Kv7 channel-
blockers XE-991 and linopirdine (which discrimi-
nate only poorly among channels formed by
different Kv7 subunits) inhibited a sustained mem-
brane conductance and depolarized the resting
membrane potential of portal vein myocytes (115).
Both drugs also increased the spontaneous con-
tractile activity of whole portal veins, suggesting
that in smooth muscle cells, similar to neurons,
Kv7 channels provide membrane hyperpolariza-
tion under resting conditions, thereby suppressing
membrane excitability. Consistent with this, the
increased membrane excitability of smooth muscle
cells in vitro produced by arginine-vasopressin de-
pends on the inhibition of constitutively active Kv7
channels (13). Retigabine and flupirtine, two Kv7
activators that do not act on Kv7 channels com-
posed of Kv7.1 subunits, are effective as vasorelax-
ants, suggesting that Kv7.1-containing channels
are not involved. In fact, later experiments revealed
that, among Kv7s, Kv7.4 is the most abundant
mRNA in mouse aorta, carotid artery, femoral ar-
tery, and mesenteric artery (116). Also in visceral
adipose tissue and mesenteric human arteries,
Kv7.4 mRNA is consistently expressed, whereas ex-
pression of Kv7.1, Kv7.3, and Kv7.5 mRNAs is more
variable and Kv7.2 mRNA is undetectable
(FIGURE 1). In these tissues, Kv7 subunits are located
in the smooth muscle layer (68). Kv7.4 and Kv7.5
genes are also expressed in different regions of the
murine gastrointestinal tract (colon, jeuneum,
stomach). In the distal colon, the Kv7 activator
retigabine inhibited spontaneous contractile activ-
ity by a dual action on myenteric nerves and on the
smooth muscle; by contrast, Kv7 channel blockers
augment inherent contractile activity, thereby ap-
pearing as promising therapeutics for the treat-
ment of motility disorders such as constipation
associated with irritable bowel syndrome (41).
Finally, it is worth noticing that in C2C12 cells, a
widely used in vitro model of skeletal muscle dif-
ferentiation, Kv7.2, Kv7.3, and Kv7.4 mRNAs have
been detected (40), in addition to Kv7.1 and Kv7.5
transcripts (53, 78, 87). Moreover, Kv7.1, Kv7.3, and
Kv7.4 transcripts, but not those for Kv7.2 and
Kv7.5, were upregulated upon in vitro myotube
formation, with Kv7.4 showing the largest increase.
Pharmacological experiments revealed that Kv7
channels, and Kv7.4 in particular, regulate skeletal
muscle proliferation, differentiation, and respon-
ses to drug-induced myotoxic effects, thereby ex-
panding the potential pathophysiological and
pharmacological role of Kv7 channels.
Kv7.5
Kv7.5 was the last member of the Kv7 gene family
to be identified (53, 87). Kv7.5 transcripts are ex-
pressed in the brain and in sympathetic ganglia,
showing a distribution largely overlapping those
for Kv7.2 and Kv7.3 (87). In Xenopus oocytes, ho-
momeric Kv7.5 channels generate depolarization-
activated K-selective currents with very slow
activation kinetics, requiring several seconds to
fully activate. Kv7.5 subunits do not co-assemble
with Kv7.2 subunits but do so with Kv7.3 and Kv7.4
subunits (14). Interestingly, Kv7.5 can reduce het-
eromeric currents produced by the simultaneous
expression of Kv7.2 and Kv7.3 subunits, possibly by
decreasing the amount of Kv7.3 subunits available
to form the more “efficient” Kv7.2/Kv7.3 hetero-
mers. Since all three Kv7 subunits are broadly ex-
pressed in the brain and show an overlapping
cellular pattern of expression (94), it has been pro-
posed that Kv7.5 subunits contribute to the func-
tional variety of IKM in distinct neuronal
population. In addition to neuronal cells, Kv7.5
transcripts and/or proteins have also been identi-
fied in nonneuronal tissues, such as skeletal (40,
78, 116a) and smooth muscle cells (116). Kv7.5
transcripts and proteins have been identified in the
tunica media from various blood vessels, where
they participate in vascular tone regulation (13)
(FIGURE 1). Onemajor limitation in investigating the
pathophysiological role of Kv7.5 channels (and of
Kv7 channels in general) is the lack of pharmacological
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tools selectively targeting distinct Kv7 subunits; in
this scenario, the recently described ability of the
well known anti-inflammatory drug diclofenac to
suppress Kv7.5 while activating Kv7.4 channels (14)
may allow a more precise definition of the specific
pathophysiological role of Kv7.5 subunits at each
cellular site of expression.
Conclusions
In 2011, we will celebrate 15 years since the mo-
lecular identification of Kv7.1, the first member of
the Kv7 potassium channel gene family. Since
then, our understanding of the molecular patho-
genesis of Kv7 channelopathies and of the physio-
logical role played by distinct Kv7 subunits
underlying cardiac IKs, neural IKM, and IKM-like K

currents in several cell types has grown exponen-
tially. Research on Kv7 channels has always pro-
ceeded with a strong translational emphasis; the
benefits of this approach are likely to be seen in the
near future, where Kv7-based pharmacological
strategies are likely going to be available for the
treatment of human diseases. The Kv7 activator
retigabine has been recently approved as an anti-
convulsant in Europe and awaits US approval (6,
67a). Additional indications for Kv7 modulators
range from pain to arrhythmias, hypertension, and
primary sensory dysfunctions, whose common
pathogenetic theme is the alteration in cellular
excitability controlled by this unique class of volt-
age-gated K channels. 
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